17 results on '"bone morphogenetic protein receptor type II"'
Search Results
2. UVA causes dysfunction of ETBR and BMPR2 in vascular endothelial cells, resulting in structural abnormalities of the skin capillaries.
- Author
-
Miyachi, Katsuma, Murakami, Yuhko, Inoue, Yu, Yoshioka, Hisashi, Hirose, Osamu, Yamada, Takaaki, Hasegawa, Seiji, Arima, Masaru, Iwata, Yohei, Sugiura, Kazumitsu, and Akamatsu, Hirohiko
- Subjects
- *
VASCULAR endothelial cells , *CAPILLARIES , *BONE morphogenetic protein receptors - Abstract
• Capillary structural abnormalities on sun-exposed skin with skin redness unevenness. • Capillary structural abnormalities include dilation and disappearance. • Capillaries are excessively dilated by increased ETBR expression on HUVECs by UVA. • Capillary migration disappears under decreased BMPR2 expression on HUVECs by UVA. Capillary structural abnormalities cause skin disorders. Mottled redness, i.e., skin redness unevenness, may appear on the sun-exposed skin, suggesting capillary structural abnormalities, although its mechanism remains unclear. To observe the capillary structures in the sun-exposed skin where skin redness unevenness is likely to occur, and clarify the mechanism of capillary structural abnormalities. The tissue structures in the skin with skin redness unevenness were observed by LC-OCT. Subsequently, immunostaining of the sun-exposed skin where skin redness unevenness is often observed, was performed. Vascular endothelial cells were UV-irradiated to analyze the expression and functions of genes involved in the capillary structures and morphogenesis. The skin with skin redness unevenness exhibited scattering of dilated tubular tissue and disturbance of distribution uniformity. Immunostaining of the sun-exposed skin that were more likely to be exposed to UV rays also revealed similarly disorder of capillary structures. In addition, UVA-irradiated vascular endothelial cells exhibited increased expression of ETBR, involved in telangiectasia, decreased expression of BMPR2, involved in the morphogenesis and maintenance of the blood vessels, and reduced migration of the capillaries. UV rays alter ETBR and BMPR2 expression in the skin capillaries, and cause partial dilation and decreased migration, resulting in capillary structural abnormalities and causing skin redness unevenness. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Transgenic and Gene-Targeted Mouse Models for Pulmonary Hypertension
- Author
-
West, James D., Yuan, Jason X. -J., editor, Garcia, Joe G.N., editor, West, John B., editor, Hales, Charles A., editor, Rich, Stuart, editor, and Archer, Stephen L., editor
- Published
- 2011
- Full Text
- View/download PDF
4. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Genetics of pulmonary hypertension
- Author
-
Qadar Pasha
- Subjects
Bone morphogenetic protein receptor type II ,transforming gtowth factors ,activin receptor-like kinase 1 ,endoglin ,genetics ,pulmonary hypertension ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Pulmonary hypertension (PH) is a phenotype characterized by functional and structural changes in the pulmonary vasculature, leading to increased vascular resistance. [1],[2] The World Health Organization has classified PH into five different types: arterial, venous, hypoxic, thromboembolic or miscellaneous; details are available in the main guidelines. Group I of this classification, designated as pulmonary arterial hypertension (PAH), will remain the main focus here. The pathophysiology involves signaling, endothelial dysfunction, activation of fibroblasts and smooth muscle cells, interaction between cells within the vascular wall, and the circulating cells; as a consequence plexiform lesions are formed, which is common to both idiopathic and heritable PAH but are also seen in other forms of PAH. [2],[3],[4] As the pathology of PAH in the lung is well known, this article focuses on the genetic aspects associated with the disease and is a gist of several available articles in literature.
- Published
- 2014
- Full Text
- View/download PDF
5. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
- Author
-
Soon, Elaine, Crosby, Alexi, Southwood, Mark, Peiran Yang, Tajsic, Tamara, Toshner, Mark, Appleby, Sarah, Shanahan, Catherine M., Bloch, Kenneth D., Pepke-Zaba, Joanna, Upton, Paul, Morrell, Nicholas W., and Yang, Peiran
- Subjects
THERAPEUTIC use of antioxidants ,OXIDES ,ANIMAL experimentation ,ANIMALS ,CELL receptors ,CYTOKINES ,DISEASE susceptibility ,FREE radicals ,IMMUNOHISTOCHEMISTRY ,MICE ,PULMONARY hypertension ,RESEARCH funding ,SUPEROXIDE dismutase ,ORCIPRENALINE ,THERAPEUTICS - Abstract
Rationale: Mutations in bone morphogenetic protein receptor type II (BMPR-II) underlie most cases of heritable pulmonary arterial hypertension (PAH). However, disease penetrance is only 20-30%, suggesting a requirement for additional triggers. Inflammation is emerging as a key disease-related factor in PAH, but to date there is no clear mechanism linking BMPR-II deficiency and inflammation.Objectives: To establish a direct link between BMPR-II deficiency, a consequentially heightened inflammatory response, and development of PAH.Methods: We used pulmonary artery smooth muscle cells from Bmpr2(+/-) mice and patients with BMPR2 mutations and compared them with wild-type controls. For the in vivo model, we used mice heterozygous for a null allele in Bmpr2 (Bmpr2(+/-)) and wild-type littermates.Measurements and Main Results: Acute exposure to LPS increased lung and circulating IL-6 and KC (IL-8 analog) levels in Bmpr2(+/-) mice to a greater extent than in wild-type controls. Similarly, pulmonary artery smooth muscle cells from Bmpr2(+/-) mice and patients with BMPR2 mutations produced higher levels of IL-6 and KC/IL-8 after lipopolysaccharide stimulation compared with controls. BMPR-II deficiency in mouse and human pulmonary artery smooth muscle cells was associated with increased phospho-STAT3 and loss of extracellular superoxide dismutase. Chronic lipopolysaccharide administration caused pulmonary hypertension in Bmpr2(+/-) mice but not in wild-type littermates. Coadministration of tempol, a superoxide dismutase mimetic, ameliorated the exaggerated inflammatory response and prevented development of PAH.Conclusions: This study demonstrates that BMPR-II deficiency promotes an exaggerated inflammatory response in vitro and in vivo, which can instigate development of pulmonary hypertension. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
6. Connexin-mediated regulation of the pulmonary vasculature.
- Author
-
Dempsie, Yvonne, Martin, Patricia, and Upton, Paul D.
- Subjects
- *
CELL communication , *CONNEXINS , *HEART failure , *PULMONARY blood vessels , *PULMONARY hypertension - Abstract
Pulmonary arterial hypertension (PAH) is a complex, multi-factorial disorder characterized by both constriction and remodelling of the distal pulmonary vasculature. This leads to increased pulmonary pressures and eventually right heart failure. Current drugs, which primarily target the vasoconstriction, serve only to prolong life and novel therapies targeting both the vasoconstriction and the remodelling are required. Aberrant signalling between cells of the pulmonary vasculature has been associated with the development of PAH. In particular, endothelial dysfunction can lead to hyperplasia of the underlying medial layer. Connexins are a family of transmembrane proteins which can form intercellular communication channels known as gap junctions. This review will discuss recent evidence which shows that connexins play a role in regulation of the pulmonary vasculature and that dysregulation of connexins may contribute to PAH pathogenesis. Interaction of connexins with signalling pathways relevant to the pathogenesis of PAH, such as bone morphogenetic protein (BMP), serotonin and oestrogen are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Guidelines. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Genetics of pulmonary hypertension.
- Author
-
Pasha, Qadar
- Subjects
- *
PULMONARY hypertension treatment , *PULMONARY hypertension diagnosis , *PULMONARY hypertension , *MEDICAL protocols , *GENETICS - Abstract
Pulmonary hypertension (PH) is a phenotype characterized by functional and structural changes in the pulmonary vasculature, leading to increased vascular resistance. The World Health Organization has classified PH into five different types: arterial, venous, hypoxic, thromboembolic or miscellaneous; details are available in the main guidelines. Group I of this classification, designated as pulmonary arterial hypertension (PAH), will remain the main focus here. The pathophysiology involves signaling, endothelial dysfunction, activation of fibroblasts and smooth muscle cells, interaction between cells within the vascular wall, and the circulating cells; as a consequence plexiform lesions are formed, which is common to both idiopathic and heritable PAH but are also seen in other forms of PAH. As the pathology of PAH in the lung is well known, this article focuses on the genetic aspects associated with the disease and is a gist of several available articles in literature. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells.
- Author
-
Lagna, Giorgio, Nguyen, Peter H., Weihua Ni, and Hata, Akiko
- Subjects
- *
BONE morphogenetic proteins , *GROWTH factors , *GENETIC mutation , *LIGAND binding (Biochemistry) , *APOPTOSIS , *PULMONARY artery , *CELL death - Abstract
Germ line mutations in the bone morphogenetic protein (BMP) receptor type II (BMPRII) gene have been found in >50% of familial idiopathic puhnonary arterial hypertension (IPAH) patients and in 30% of sporadic cases of IPAH. Mutations of BMPRII occur in the extracellular ligand-binding domain, in the cytoplasmic serine/threonine kinase domain, or in the long carboxy terminus domain of unknown function. [n this study, we demonstrate that BMPs promote apoptotic cell death in normal human pulmonary artery smooth muscle cells (PASMCs) by activation of caspases-3, -8, and -9, cytochrome c release, and downregulation of Bcl-2. Normal PASMCs expressing a kinase domain mutant or a carboxy-terminal domain deletion mutant of BMPRII identified in IPAH patients are resistant to BMP-mediated apoptosis. This dominant-negative effect may act in heterozygous patients and lead to the development of the pulmonary vascular medial hypertrophy found in IPAH patients. Our study also demonstrates an essential role of the carboxy terminus domain of BMPRII in the activation of the apoptotic signaling cascade. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
9. Bone Morphogenetic Protein Receptor Type II C-Terminus Interacts with c-Src.
- Author
-
Wai K. P. Wong, Knowles, James A., and Morse, Jane H.
- Published
- 2005
- Full Text
- View/download PDF
10. Pediatric pulmonary veno-occlusive disease associated with a novel BMPR2 variant.
- Author
-
Takemori W, Yamamura K, Tomita Y, Egami N, Eguchi K, Nagata H, Shirouzu H, Ishikawa Y, Nakajima D, Yoshizawa A, Date H, and Ohga S
- Subjects
- Bone Morphogenetic Protein Receptors, Type II genetics, Child, Child, Preschool, Familial Primary Pulmonary Hypertension, Humans, Lung, Male, Hypertension, Pulmonary diagnosis, Lung Transplantation adverse effects, Pulmonary Veno-Occlusive Disease complications, Pulmonary Veno-Occlusive Disease diagnostic imaging, Pulmonary Veno-Occlusive Disease genetics
- Abstract
Pulmonary veno-occlusive disease (PVOD) and idiopathic/heritable pulmonary arterial hypertension (I/HPAH) cause progressive PH on the distinct genetic impact. A 29-month-old boy presented with a loss of consciousness. He had severe PH refractory to pulmonary vasodilators. Hypoxemia and ground-glass opacity on the chest computed tomography were present, and significant pulmonary edema developed after the introduction of continuous intravenous prostaglandin I
2 . Based on the clinical diagnosis of PVOD, he underwent a single living-donor lobar lung transplantation with the right lower lobe of his mother. The pathological findings of his explanted lung showed intimal thickening and luminal narrowing of the pulmonary vein. A genetic test revealed a novel heterozygous splice acceptor variant (c.77-2A>C) in BMPR2, which is typically associated with I/HPAH. This is the first pediatric case of PVOD with BMPR2 variant, supporting the concept that I/HPAH and PVOD are part of a spectrum of pulmonary vascular disease., (© 2022 Wiley Periodicals LLC.)- Published
- 2022
- Full Text
- View/download PDF
11. Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling
- Author
-
Ji-Ae Jang, Youn-Kwan Jung, Seungwoo Han, and Sun Ha Choi
- Subjects
bone morphogenetic protein receptor type II ,frameshift mutation ,DNA Mutational Analysis ,Bone Morphogenetic Protein Receptors, Type II ,medicine.disease_cause ,Bone morphogenetic protein ,Frameshift mutation ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,pulmonary arterial hypertension ,medicine ,Humans ,Familial Primary Pulmonary Hypertension ,Bone morphogenetic protein receptor ,Clinical Case Report ,030212 general & internal medicine ,Gene ,Mutation ,business.industry ,DNA ,General Medicine ,anti-Müllerian hormone receptor type 2 ,BMPR2 ,030220 oncology & carcinogenesis ,Bone Morphogenetic Proteins ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Cancer research ,Female ,Signal transduction ,business ,Research Article ,Signal Transduction ,Transforming growth factor - Abstract
Supplemental Digital Content is available in the text, Rationale: Idiopathic pulmonary arterial hypertension (IPAH) is characterized by intense remodeling of small pulmonary arteries. Loss-of-function mutation of bone morphogenetic protein receptor II (BMPR2) gene and exaggerated activation of transforming growth factor (TGF)-β signaling play a critical role in this process. Patient concerns and diagnosis: We report a novel frameshift mutation (c.117InsT, p.Y40fsX48) of the BMPR2 gene identified in a 19-year-old IPAH patient with syncope. Despite BMPR2 mutation, the phosphorylation of Smad2/3 and Samd1/5/8 was increased in the patient's peripheral blood mononuclear cells, and this event was accompanied by the upregulation of bone morphogenetic protein (BMP) signaling target genes, but not TGF-β signaling target genes. Moreover, we observed an increased expression of other BMPRs, that is, anti-Mullerian hormone type-2 receptor and the activin receptor-like kinases (ALK) 1, ALK3, and ALK6. Interventions and outcomes: The patient was prescribed a combination of macitentan, sildenafil, and nifedipine, which successfully controlled her symptom of syncope and normalized N-terminal pro-brain natriuretic peptide level after 3 months of medication. Lessons: In light of these results, we propose a new pathogenetic mechanism for IPAH, based on enhanced BMP signaling via the functional replacement of mutated BMPR2 by other BMP receptors.
- Published
- 2019
- Full Text
- View/download PDF
12. Spatiotemporal expression of activin receptor-like kinase-5 and bone morphogenetic protein receptor type II in the ovary of shortfinned eel, Anguilla australis.
- Author
-
Falahati, Ali, Ozaki, Yuichi, Damsteegt, Erin L., Zadmajid, Vahid, Freeman, Kaitlyn J., and Lokman, P. Mark
- Subjects
- *
BONE morphogenetic protein receptors , *ANGUILLA anguilla , *OVARIES , *EELS , *SOMATIC cells , *GERM cells - Abstract
In the eel ovary, the expression of growth differentiation factor-9 (Gdf9) appears to be largely confined to the germ cell in early stages of oogenesis. However, both the target tissue and the function of Gdf9 in fish remain unknown. This study aimed to describe the abundance and localization of activin receptor-like kinase-5 (Alk5) and bone morphogenetic protein receptor type II (Bmpr2), which together mediate the Gdf9 signal, in the ovary of a basal teleost, the shortfinned eel, Anguilla australis , during early folliculogenesis. The cDNA encoding eel alk5 and bmpr2 genes were cloned, characterized and the transcript abundances of these receptors quantified by quantitative real-time PCR. Ovarian transcript abundance for both receptors, along with that of gdf9 and of its paralogue bmp15 , increased from the previtellogenic to early vitellogenic stage. Localization of receptor mRNAs by in situ hybridization revealed that these receptors are located in the somatic cells surrounding the oocyte. Furthermore, tissue distribution analysis showed that the expression of alk5 and bmpr2 were highest in ovary and thyroid, respectively. Unexpectedly, however, bmpr2 mRNA levels were lower in the ovary than in any of the other 17 tissues examined, and indeed, lower than ovarian gdf9 transcript abundance. These findings, together with the ovarian expression pattern of Gdf9, suggest that Gdf9, and conceivably, Bmp15, from the oocyte can signal through receptors that are located on the somatic cells surrounding the oocyte; this, in turn, facilitates elucidation of the function of these growth factors during oogenesis in teleost fish. Unlabelled Image • Transcripts for alk5 and bmpr2 are located in the somatic cells surrounding the oocyte in shortfinned eel • Expression of both Alk5 and Bmpr2 along with that of their ligand(s), increased • Among 18 tissues examined, the expression of alk5 was highest, and that of bmpr2 was lowest, in the ovary [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Gender, sex hormones and pulmonary hypertension
- Author
-
Abdallah Alzoubi, Masahiko Oka, Stevan P. Tofovic, James West, Margaret R. MacLean, Anne Katrine Johansen, Eric D. Austin, and Tim Lahm
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,bone morphogenetic protein receptor type II ,medicine.drug_class ,Dehydroepiandrosterone ,Physiology ,Disease ,Review Article ,030204 cardiovascular system & hematology ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Sex hormone-binding globulin ,dehydroepiandrosterone ,Internal medicine ,pulmonary hypertension ,medicine ,estrogen ,030304 developmental biology ,0303 health sciences ,biology ,business.industry ,medicine.disease ,Pulmonary hypertension ,3. Good health ,BMPR2 ,serotonin ,Endocrinology ,Estrogen ,biology.protein ,business ,Hormone - Abstract
Most subtypes of pulmonary arterial hypertension (PAH) are characterized by a greater susceptibility to disease among females, although females with PAH appear to live longer after diagnosis. While this “estrogen paradoxȍ of enhanced female survival despite increased female susceptibility remains a mystery, recent progress has begun to shed light upon the interplay of sex hormones, the pathogenesis of pulmonary hypertension, and the right ventricular response to stress. For example, emerging data in humans and experimental models suggest that estrogens or differential sex hormone metabolism may modify disease risk among susceptible subjects, and that estrogens may interact with additional local factors such as serotonin to enhance the potentially damaging chronic effects of estrogens on the pulmonary vasculature. Regardless, it remains unclear why not all estrogenic compounds behave equally, nor why estrogens appear to be protective in certain settings but detrimental in others. The contribution of androgens and other compounds, such as dehydroepiandrosterone, to pathogenesis and possibly treatment must be considered as well. In this review, we will discuss the recent understandings on how estrogens, estrogen metabolism, dehydroepiandrosterone, and additional susceptibility factors may all contribute to the pathogenesis or potentially to the treatment of pulmonary hypertension, by evaluating current human, cell-based, and experimental model data.
- Published
- 2013
14. Identificación de mutaciones en el gen del receptor de proteínas morfogéneticas óseas tipo II (BMPRII) en pacientes pediátricos con hipertensión arterial pulmonar familiar e idiopática de la ciudad de Bogotá
- Author
-
Moreno Pinzón, Christian Camilo, Díaz Gongora, Gabriel Fernando (Thesis advisor), Ruiz Parra, Ariel Iván (Thesis advisor), Rey Buitrago, Mauricio (Thesis advisor), and Arteaga Díaz, Clara Eugenia
- Subjects
Pulmonary Hypertension ,Hipertensión Arterial Pulmonar ,Bone morphogenetic protein receptor type II ,51 Matemáticas / Mathematics ,61 Ciencias médicas ,Medicina / Medicine and health ,Idiopathic Pulmonary Arterial ,Receptor de proteínas morfogenéticas óseas tipo II ,Arterial Pulmonar Idiopática ,Hipertensión Arterial Pulmonar Familiar ,Hypertension Pulmonary Arterial Family - Abstract
La Hipertensión Arterial Pulmonar (HAP) es una enfermedad poco frecuente y de causa desconocida. La HAP comprende varios subgrupos y dentro de ellos se encuentra la Hipertensión Arterial Pulmonar Idiopática (HAPI) y la Hipertensión Arterial Pulmonar Familiar (HAPF). Se postula la existencia de una predisposición genética porque mutaciones en el gen BMPRII (gen de receptor de proteínas morfogenéticas óseas tipo II) responsable del mantenimiento de la fisiología vascular pulmonar, están implicadas en más del 75% de los casos de HAP familiar y del 10 - 25% de la presentación idiopática, sin embargo, tan solo del 10 al 20% de los portadores de la mutación expresan fenotípicamente la enfermedad. De esta manera, el objetivo del presente estudio fue determinar por medio de secuenciación génica la presencia de mutaciones en el gen del receptor de proteínas morfogenéticas óseas tipo II (BMPRII) en 19 pacientes pediátricos con HAPI y HAPF con el fin de clasificar las mutaciones presentes y evaluar la correlación entre la presencia o ausencia de la mutación en dicho gen y la severidad de la hipertensión arterial pulmonar. De un total de 19 sujetos estudiados se encontró la nueva mutación V21A en el exón 1 de BMPR2, representando el 5% de la población de estudio en un caso de HAPI. Mediante estudios de simulación in silico se estableció que la funcionalidad del receptor fue comparable con resultados de simulaciones del receptor tipo silvestre. Nuestro estudio es el primero que analiza la presencia de mutaciones en BMPRII en pacientes pediátricos con HAP en altura, demostrando que las mutaciones en el gen BMPRII son también causa de HAP en población pediátrica. Abstract. Pulmonary Arterial Hypertension (PAH) is a rare disease of unknown cause. PAH comprises several subgroups and within them are Idiopathic Pulmonary Arterial Hypertension (IPAH) and Family Pulmonary Arterial Hypertension (FPAH). The existence of a genetic predisposition BMPRII mutations responsible gene (bone morphogenetic receptor type II protein) lung maintenance of vascular physiology, are implicated in over 75 % of cases of familial PAH is postulated and 10 - 25 % of idiopathic presentation, however, only 10 to 20 % of mutation carriers phenotypically express the disease. Thus, the objective of this study was determined by gene sequencing for the presence of mutations in the receptor bone morphogenetic protein type II (BMPRII) in patients 19 pediatric IPAH and HAPF order to classify the mutations present and evaluating the correlation between the presence or absence of the mutation in the gene and the severity of pulmonary arterial hypertension. From a total of 19 subjects studied new V21A mutation was found in exon 1 of BMPR2 representing 5% of the study population in a case of HAPI. Simulation studies were established in silico receptor functionality that was comparable with results of simulations of the wild type receptor. Our study is the first to analyze the presence of mutations in BMPRII in pediatric patients with PAH in height, demonstrating that mutations in BMPRII gene also cause PAH in pediatric population. Maestría
- Published
- 2014
15. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Genetics of pulmonary hypertension.
- Author
-
Pasha Q
- Abstract
Pulmonary hypertension (PH) is a phenotype characterized by functional and structural changes in the pulmonary vasculature, leading to increased vascular resistance.[12] The World Health Organization has classified PH into five different types: arterial, venous, hypoxic, thromboembolic or miscellaneous; details are available in the main guidelines. Group I of this classification, designated as pulmonary arterial hypertension (PAH), will remain the main focus here. The pathophysiology involves signaling, endothelial dysfunction, activation of fibroblasts and smooth muscle cells, interaction between cells within the vascular wall, and the circulating cells; as a consequence plexiform lesions are formed, which is common to both idiopathic and heritable PAH but are also seen in other forms of PAH.[234] As the pathology of PAH in the lung is well known, this article focuses on the genetic aspects associated with the disease and is a gist of several available articles in literature.
- Published
- 2014
- Full Text
- View/download PDF
16. Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetics.
- Author
-
Zhang H, Zhao T, Gong Y, Dong X, Zhang W, Sun S, Wang H, Gu Y, Lu X, Yan M, and Li P
- Subjects
- Animals, Blood Glucose, Chemokine CCL2 genetics, Chemokine CCL2 metabolism, Drug Administration Schedule, Drugs, Chinese Herbal chemistry, Fosinopril therapeutic use, Gene Expression Regulation, Kidney drug effects, Kidney metabolism, Male, Molecular Structure, Rats, Rats, Wistar, Transcription Factor RelA genetics, Transcription Factor RelA metabolism, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha metabolism, Anti-Inflammatory Agents therapeutic use, Diabetes Mellitus, Experimental drug therapy, Drugs, Chinese Herbal therapeutic use, Hypoglycemic Agents therapeutic use
- Abstract
Ethnopharmacological Relevance: Traditional Chinese medical herbs have been used in China for a long time to treat different diseases. Based on traditional Chinese medicine (TCM) principle, Chaihuang-Yishen granule (CHYS) was developed and has been employed clinically to treat chronic kidney disease including diabetic nephropathy (DN). The present study was designed to investigate its mechanism of action in treatment of DN., Materials and Methods: Diabetic rats were established by having a right uninephrectomy plus a single intraperitoneal injection of STZ. Rats were divided into four groups of sham, diabetes, diabetes with CHYS and diabetes with fosinopril. CHYS and fosinopril were given to rats by gavage for 20 weeks. Samples from blood, urine and kidney were collected for biochemical, histological, immunohistochemical and molecular analyses., Results: Rats treated with CHYS showed reduced 24h urinary protein excretion, decreased serum TC and TG levels, but CHYS treatment did not affect blood glucose level. Glomerular mesangial expansion and tubulointerstitial fibrosis in diabetic rats were significantly alleviated by CHYS treatment. Moreover, CHYS administration markedly reduced mRNA levels of NF-κB p65 and TGF-β1, as well as decreased protein levels of NF-κB p65, MCP-1, TNF-α and TGF-β1 in the kidney of diabetic rats., Conclusions: CHYS ameliorates renal injury in diabetic rats through reduction of inflammatory cytokines and their intracellular signaling., (© 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
17. Gender, sex hormones and pulmonary hypertension.
- Author
-
Austin ED, Lahm T, West J, Tofovic SP, Johansen AK, Maclean MR, Alzoubi A, and Oka M
- Abstract
Most subtypes of pulmonary arterial hypertension (PAH) are characterized by a greater susceptibility to disease among females, although females with PAH appear to live longer after diagnosis. While this "estrogen paradoxȍ of enhanced female survival despite increased female susceptibility remains a mystery, recent progress has begun to shed light upon the interplay of sex hormones, the pathogenesis of pulmonary hypertension, and the right ventricular response to stress. For example, emerging data in humans and experimental models suggest that estrogens or differential sex hormone metabolism may modify disease risk among susceptible subjects, and that estrogens may interact with additional local factors such as serotonin to enhance the potentially damaging chronic effects of estrogens on the pulmonary vasculature. Regardless, it remains unclear why not all estrogenic compounds behave equally, nor why estrogens appear to be protective in certain settings but detrimental in others. The contribution of androgens and other compounds, such as dehydroepiandrosterone, to pathogenesis and possibly treatment must be considered as well. In this review, we will discuss the recent understandings on how estrogens, estrogen metabolism, dehydroepiandrosterone, and additional susceptibility factors may all contribute to the pathogenesis or potentially to the treatment of pulmonary hypertension, by evaluating current human, cell-based, and experimental model data.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.